Skip to main content

Read more about our corporate brand here.

Search
Search
Startup Strategy

Life science startup hubs: Advantages of Texas

Key takeaways

  • Texas is quickly rising as a hub for life science startups.
  • The state offers a $4 billion taxpayer-funded grant program for oncology, among other incentives.
  • Houston's giant academic, research and clinical medical complex, Texas Medical Center, is a draw for startups looking for access to a broad and diverse population.

Beyond the firm's splashy magazine covers, biotech startup Volumetric is developing synthetic organs with a vascular architecture that mimics those inside the human body. Volumetric's tech is promising enough that healthcare giant 3D Systems recently scooped up the startup in a deal worth up to $400 million.

Interestingly, this research, development, and deal-making didn't go down in one of America's two major life science hubs: Silicon Valley or Boston-Cambridge. It happened in Texas, specifically Houston, a rising center for life science startups. Houston's healthcare sector is surging, fed by a boom in lab space, research dollars, talent and funding.

And talent is following. A good example is Fiona Mack, Head of Johnson & Johnson Innovation - JLABS at the Texas Medical Center, a 34,000 square foot startup accelerator and biotech incubator space. Mack, like many other Texas biotech stars, isn't a native to Texas; she moved from the NYC metro area two years ago. "I was impressed by the talent in Texas and certainly the possibilities that exist in the life sciences here," says Mack. Here's why Mack, and many others, are choosing the Lone Star state.

1. Incubator opportunities are opening up

Texas tends to go big. And you wouldn't argue with the statement once you've seen the Texas Medical Center (TMC), a medical complex in Houston that serves 10 million patients a year and has $3 billion worth of construction projects underway. One of its tenants is JLABS, where oncology, pharmaceuticals and medical device-related startups utilize wet lab space and other hardware. Startups also benefit from all the nearby brainpower.

"Every founder that comes into JLABS is paired with a mentor within Johnson & Johnson, who gives them access to the entire enterprise of expertise that would come with such a large pharma presence. We also make introductions to our investor community," says Mack.

JLABS is not the only incubator in Houston. Nearby, the year-old K2bio hosts nearly 30,000 square feet of space for early-stage life science startups with wet lab space and an onsite vivarium capable of hosting 6,000 mice. Co-Founder Andrew Strong says the idea is to help drug developers stretch their arms as they develop preclinical studies and conduct process and analytical activities.

"They can use our office, our dedicated lab space, and our high-end pharmacodynamic imaging, process development and analytical equipment. We handle the supply chain. We're letting these companies focus more on their science, and less on the logistics."

Houston doesn't hold a monopoly on incubator space. Up north in Dallas, BioLabs recently opened a 37,000-square-foot flexible life science facility with space for 35 startups. And on San Antonio's east side, the two-year-old VelocityTx hosts 17,000 square feet of collaborative space for biotech innovators, with expansion plans to create an innovation district. In Austin, UT Austin's Dell Medical School runs CoLab, a launchpad for health innovations aimed at easing the path to market.

Strong says that each of the big Texas cities has become a hotspot of health innovation. "In Houston, you see a lot of work in cell therapies, cancer and infectious diseases. In Dallas, you see rare genetic and brain, and CNS diseases. And in Austin and San Antonio, you see a lot of device and med tech innovation. You're starting to see these centers of excellence grow."

There are a lot of different tools and levers that makes Texas unique. Not that other states aren't doing unique things, but I think Texas does well by luring companies here, then finding ways to continue supporting them.

2. Strong incentives, especially in oncology

Startups and established companies are moving to Texas for several reasons: The taxes are lower, the regulations are fewer and housing, in much of the state, costs less than in most of California. A lesser-known motivation is the growing pool of incentives aimed at biotech innovators. The largest grant programs come from the Cancer Prevention and Research Institute of Texas (CPRIT). It's the largest state cancer research investment in the history of the US. CPRIT has doled out $3 billion to research institutions, early-stage companies and more, all focused on oncology, and has another $3 billion to spend.

"It's a unique program," says Mack. "It does two things. One, for companies that started in Texas, it provides some guidance for their next funding milestones. And two, it also attracts talent from all across the country, whether it's funding the product development of a therapeutic device or bringing in academic researchers to a campus. These are the types of folks that have the entrepreneurial spirit to start the companies that might change the fight against cancer."

While CPRIT is focused solely on oncology, the number of grants for life science startups across the board is also growing. Take for example the Texas Medical Center's Venture Fund, a $50 million initiative to fund early-stage companies developing therapeutics, medical devices, and more; the Cancer Focus Fund, another $75 million in committed capital and expertise, and philanthropies like the Lyda Hill, aimed at early-stage discovery science.

"There are a lot of different tools and levers that make Texas unique. Not that other states aren't doing unique things, but I think Texas does well by luring companies here, then finding ways to continue supporting them," says Strong. For example, New York has a collection of state tax incentive programs that can make it a very desirable location for an LSHC founder.

Texas is at a stage of the development story where, when a life science company goes under, its talent gets quickly reabsorbed into new companies, and they become the next leaders. That happens all the time in Boston and San Francisco. But we're seeing it now in Texas.

Andrew Strong

3. A steady stream of life science grads

"In terms of talent pool, it's definitely here," says Mack. Texas boasts fifteen medical universities, including Rice University, The University of Texas and Texas A&M, all partners in the TMC3 collaborative research campus at the Texas Medical Center. "Innovators are starting companies here, attracted by the translational research that's possible" at the TMC behemoth, says Mack. A steady flow of 18,000 statewide healthcare and life science graduates per year helps. The total industry workforce nears 100,000, the fifth-largest biotech workforce in the country.

Strong says he's seen a sea change in career growth here. "Texas is at a stage of the development story where, when a life science company goes under, its talent gets quickly reabsorbed into new companies, and they become the next leaders. That happens all the time in Boston and San Francisco. But we're seeing it now in Texas: When companies turn over, executives are staying here."

4. Growing investment opportunities

While Texas may not be considered in the same tier as the Bay Area or Boston in terms of VC funding, Texas is catching up. VC firms savvy to the state's booming tech scene are honing in, such as Live Oak Venture Partners, an Austin-based, early-stage focused firm that recently announced a $210 million fund targeting Texas founders, and S3 Ventures, which announced a $250 million, Texas-focused fund last month. Austin-based Santé Ventures is also a big player, recently closing their $260 million fund IV, for healthcare and life science. And that's just a start.

5. A broad patient population

Texas is an R&D powerhouse, as evidenced by its first-in-the-country ranking for clinical trials; there were 30,000 trials underway in 2020, besting both California and New York. "What's also quite distinguishing about Texas, and especially Houston, is that it has a truly highly diverse population," says Mack. "If you're thinking about developing drugs and developing devices in an institution that is driven from a clinical, translational medicine approach, that's a powerful thing."

Strong concurs. "Every company in oncology wants access to MD Anderson's patient population. They see every type of cancer in the world, and 130,000 patients at any one time, total. The biggest challenge for a clinical stage oncology company is lining up the right patient, the right drug, and the right time. Here, that's entirely possible to do."

Running a startup is hard. Visit our Startup Insights for more advice and information on the different stages of your startup's early life. And, for the latest trends in the life science and healthcare economy, check out our Healthcare Investments & Exits report.

Read next

Explore these related articles to help you stay on top of the latest data, insights and developments in the venture-backed crypto and blockchain ecosystem.

Treasury market infrastructure: How it shapes corporate cash investing US Treasuries
Read Article Article

Treasury market infrastructure: How it shapes corporate cash investing

Oct 28, 2026

Jose Sevilla, Jason Graveley

Using a Standby Letter of Credit for a commercial lease to support real estate expansion Global Trade Finance
Read Article Article

Using a Standby Letter of Credit for a commercial lease to support real estate expansion

Oct 26, 2026

Justine Nguyen, Dennis Brown

Startup expense management: Moving from manual processes to scalable controls Spend Management
Read Article Article

Startup expense management: Moving from manual processes to scalable controls

Oct 23, 2026

Angela Sellers

More about the authors


The views expressed in this article are solely those of the author and do not necessarily reflect the views of First Citizens Innovation Banking.

All non-SVB named companies listed throughout this document are independent third parties and are not affiliated with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company.

This material, including without limitation to the statistical information herein, is provided for informational purposes only. The material is based in part on information from third-party sources that we believe to be reliable, but which has not been independently verified by us, and, as such, we do not represent the information is accurate or complete. The information should not be viewed as tax, accounting, investment, legal or other advice, nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision. Nothing relating to the material should be construed as a solicitation, offer or recommendation to acquire or dispose of any investment, or to engage in any other transaction.

Back to top
You are now leaving First Citizens Innovation Banking

You will be directed to a different website or mobile app that has its own terms of use, visitor agreement, security and privacy policies. First Citizens Innovation Banking is not responsible for (and does not provide) any products, services or content at the third party site or app, except for the products and services that carry the First Citizens Innovation Banking name.